Cargando…
Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
INTRODUCTION: There is little information about survival of spinal muscular atrophy (SMA) patients into adulthood, in particular from population-based samples. We estimated and compared age-specific, all-cause mortality rates in patients with SMA and matched controls in a large, retrospective cohort...
Autores principales: | Viscidi, Emma, Juneja, Maneesh, Wang, Jin, Wang, Nasha, Li, Li, Farwell, Wildon, Bhan, Ishir, Makepeace, Corinne, Laird, Karen, Kupelian, Varant, Eaton, Susan, Dilley, Anne, Hall, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857352/ https://www.ncbi.nlm.nih.gov/pubmed/34936050 http://dx.doi.org/10.1007/s40120-021-00307-7 |
Ejemplares similares
-
Correction to: Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
por: Viscidi, Emma, et al.
Publicado: (2022) -
The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study
por: Viscidi, Emma, et al.
Publicado: (2021) -
Increased Risk of Venous Thromboembolism in Patients With Amyotrophic Lateral Sclerosis: Results From a US Insurance Claims Database Study
por: Kupelian, Varant, et al.
Publicado: (2023) -
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019) -
Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)